47 Spam-Free Article(s) Found
https://seekingalpha.com/news/4050710-can-jnj-reverse-loss-in-2024-on-eps-growth-eyes-on-talc-litigation?source=feed_sector_healthcare
Dec 27, 2023 - Johnson & Johnson 2024: What to Expect Wells Fargo downgraded Johnson & Johnson (JNJ) to equal weight and lowered PT to $163 from $170 as analyst expects EPS gr
0
sa:-7542181225205457092
0
https://www.zacks.com/commentary/2198609/top-stock-reports-for-jpmorgan-abbott-qualcomm-others?cid=CS-ZC-FT-research_daily-2198609
Dec 15, 2023 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm, Inc. (QCOM).
zc:7407528778198516626
0
https://seekingalpha.com/news/4045689-jnj-multiple-myeloma-therapy-outperforms-standard-of-care?source=feed_sector_healthcare
Dec 12, 2023 - Johnson & Johnson's (JNJ) multiple myeloma therapy Darzalex Faspro in combination with traditional treatments outperforms standard of care. Read more here.
0
sa:-3076942884654145356
0
https://www.zacks.com/stock/news/2196537/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar?cid=CS-ZC-FT-style_box_etf-2196537
Dec 12, 2023 - Style Box ETF report for HDV
zc:6169903458059632690
0
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
zc:7309782923386933190
0
https://www.zacks.com/commentary/2193470/top-analyst-reports-for-johnson-johnson-t-mobile-caterpillar?cid=CS-ZC-FT-research_daily-2193470
Dec 05, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS) and Caterpillar Inc. (CAT).
zc:-3188739087523409036
0
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
zc:964429687094150899
0